小儿神经母细胞瘤中胚胎干细胞因子Sox2的表达

Expression and significance of Sox2 in neuroblastoma

目的探讨胚胎干细胞因子性别决定区Y框蛋白2（Sox2）在小儿神经母细胞瘤组织中的表达及意义。方法应用免疫组化、RT-PCR、Realtime-PCR、免疫印迹等方法检测65例神经母细胞瘤和相应瘤旁组织中Sox2的表达，并分析其表达与临床病理参数的相关性。结果神经母细胞瘤组织中SOx2的表达水平明显高于瘤旁组织，两组间差异有统计学意义（P〈0．05）；Sox2在高分期肿瘤（Ⅲ～Ⅳ期）中的表达水平高于低分期肿瘤（Ⅰ～Ⅱ期），其mRNA相对表达量分别为0．0284±0．0087和0．0135±0．0075，差异有统计学意义（P〈0．05）；且未经化疗的肿瘤其SOx2的表达水平0．0284±0．0087高于经过化疗肿瘤的0．0076±0．0022，差异有统计学意义（P〈0．05）。Sox2在神经母细胞瘤组织中的表达水平与患儿性别、年龄、肿瘤部位、大小、病理分型等参数无相关性（均P〉0．05）。结论sox2在神经母细胞瘤中表达明显增高，且与其临床分期相关，提示S0x2可能参与神经母细胞瘤的发生和发展，化疗药物对其表达有抑制作用，其机制需值得进一步研究。

Objective To investigate the expression and its clinical significance of Sox2 in neuroblastoma. Methods Sox2 expression in 65 samples of neuroblastoma tissues and paracancerous tissues was determined by immunohistochemical staining, Real-time PCR, and Western blot analysis. The relationship between the expression of Sox2 and clinical data was assessed. Results Sox2 mRNA relative expression level was significantly higher in tumor tissues than that in the adjacent non- cancerous tissues （P〈0. 05）, and the relative expression levels of Sox2 in stage III and IV NB were higher compared with those in stage I and II NB （P〈 0. 05 ）. Sox2 expression was significantly decreased in the chemotherapy subgroup as compared with that of the non-chemotherapy subgroup in stage III and IV tumors （P〈0. 05）. Western blot analysis confirmed the results at the protein level. Sox2 expression was significantly correlated to the clinical stage .of NB, but not other clinicopathological parameters including patient gender and age, tumor size, location and histological classification. Conchlsions Sox2 is widely expressed in neuroblastoma and significantly correlated to the clinical stage. This suggests that the expression of Sox2 may correlate with the genesis and progression of neuroblastoma. Sox2 expression can be inhibited by chemotherapy which is worthy of further study.